A Nelson hop extract just became a serious global weight-management contender

Riding the wave, not fighting it

Most companies would look at a US$36 billion pharmaceutical juggernaut and see a wall. Calocurb saw a slipstream. The Auckland-based weight-management company has raised $27 million to fund global expansion, and the logic behind the raise is the most interesting part of the story.

The round was led by KiwiSaver provider Generate with $10 million and Icehouse Ventures with $9 million, with the remaining $8 million from wholesale investors. Icehouse has backed the company since 2021.

Icehouse Ventures partner Jason Wang put the thesis bluntly: “The prescription GLP-1 market is on track to grow from about US$36 billion to about US$217 billion by 2031, and Calocurb doesn’t compete with that wave, it rides it.” As he sees it, as millions cycle on and off injectables, demand grows for a natural, affordable way to manage appetite and hold results without rebound.

A hop, not a peptide

Calocurb’s tablets use a patented hop extract called Amarasate, grown in Motueka, Nelson. The compound came out of Crown science: researchers at what was then Plant and Food Research screened 900 plant extracts before settling on Motueka hops. The Institute for Bioeconomy Science, which absorbed Plant and Food Research in a July 2025 CRI merger, retains a 5 percent stake.

Amarasate is pitched as a natural activator of the GLP-1 hormone, the same mechanism targeted by Ozempic and Wegovy, drugs that can cost $500 to more than $1,000 per month. Crucially, it is regulated under the US Dietary Supplement Health and Education Act, meaning it is classified as a supplement, not a drug. That distinction is both the strategic asset that speeds market access and the ceiling on the claims it can make.

The evidence, honestly

The positioning only works if there is real data behind it, and there is more than most supplements can muster. A 24-week randomised controlled trial published in Obesity Pillars in August 2026 followed 150 New Zealand adults. The Calocurb group lost 4.3 percent of body weight and 4.5 kg of fat mass with no indication of muscle loss, against 0.5 percent in the placebo group. An earlier trial found the extract cut short-term calorie intake by 18 percent.

University of Auckland obesity and diabetes professor Peter Shepherd told RNZ in July 2026 that it was “a proper clinical trial under proper conditions, and it’s achieving real-world weight loss.” Massey University dietitian Dr Maria Casale called the results “very promising” but said more research was needed.

Here is the caveat worth carrying: the trial was company-funded, and as StatsChat noted in July 2026, the effect is meaningful but modest next to injected GLP-1 drugs. That isn’t a scandal. It is the product’s honest place in the market, and the market it targets is precisely the people who can’t tolerate, can’t afford, or don’t want the injectables.

The numbers are moving fast

The growth curve is doing the talking. Calocurb sold 250,000 units in 2025, up 300 percent year on year, and by the September 2026 raise it was up 200 percent year on year with 90 percent of revenue from the US. In October 2025 it signed a distribution deal with US practitioner channel Ortho Molecular. It is now entering the UK.

The tailwind reaches back to the farm. NZ Hops chief executive Blair Stewart noted in July 2026 that around 5 percent of one farm’s land is already growing Calocurb’s variety, with new plants going in to meet demand.

The model is the story

For business readers, the product matters less than the architecture. Crown IP commercialised through an equity stake, a raw material grown in Nelson, extracted in Australia, encapsulated in the US, and sold into a market the pharmaceutical industry itself is creating. Calocurb was export-focused from day one and leaned on the support ecosystem, using an NZ Export Credit guarantee with BNZ and NZTE to manage a long cash conversion cycle.

The risk is real. Non-peptide GLP-1 pills are coming, and a supplement’s claims are legally capped. But the strategy of selling maintenance to a market that churns is a genuinely smart read of where the weight-loss economy is heading. Nelson hops, once destined for beer, are now chasing a US$217 billion pharmaceutical shadow. Whether the bet pays off depends on execution, but the thesis is sound.

Sources

• Weight management supplement company Calocurb raises $27m as it looks to expand globally (2026-09-09)
• Pints to pills: how New Zealand hops can fight obesity (2026-07-28)
• Hop extract study moves beyond appetite to body composition (2026-08-03)
• NZ weight-loss ‘supplement’ works? (2026-07-30)
• New Zealand’s Wegovy and Ozempic alternative Calocurb says it’ll double its business with new US deal (2025-10-28)